Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apaziquone Post-TURBT for Noninvasive Bladder Cancer
NCT00461591Phase 3Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Apr 2007
- Primary completion
- Jan 2012
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apaziquone in bladder cancer, sponsored by Spectrum Pharmaceuticals, Inc.. Started Apr 2007; status: completed.
02
Drugs
apaziquone
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00461591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461591.